Adage Capital Partners
ITOS

Adage Capital Partners’s iTeos Therapeutics ITOS Stock Holding History

Adage Capital Partners’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,000
Closed -$219K – 895
2023
Q3 		$219K Buy
+20,000
New +$256K ﹤0.01% 796
2022
Q2 		– Sell
-105,000
Closed -$3.38M – 1113
2022
Q1 		$3.38M Sell
105,000
-65,000
-38% -$2.36M 0.01% 864
2021
Q4 		$7.92M Buy
170,000
+75,000
+79% +$2.5M 0.01% 762
2021
Q3 		$2.56M Buy
95,000
+38,107
+67% +$996K 0.01% 883
2021
Q2 		$1.46M Sell
56,893
-1,200,000
-95% -$28.6M ﹤0.01% 888
2021
Q1 		$43M Buy
1,256,893
+930,036
+285% +$33.6M 0.09% 240
2020
Q4 		$11.1M Buy
+326,857
New +$8.65M 0.02% 565

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners's ITOS Position: Q4 2023 in Review

Adage Capital Partners sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 20,000 shares — an estimated $219K sold.

Adage Capital Partners first reported a position in ITOS in Q4 2020 and held it in 7 quarters. The position peaked at $43M in Q1 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Adage Capital Partners reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Adage Capital Partners sold 20,000 iTeos Therapeutics shares in Q4 2023, an estimated $219K.
  • Adage Capital Partners first reported a position in iTeos Therapeutics in Q4 2020 and held it in 7 quarters.
  • Adage Capital Partners's iTeos Therapeutics position peaked at $43M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Adage Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.